Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel-samarium in Hormone-refractory Advanced Prostate Cancer
NCT00126230Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Jan 2004
- Countries
- 1
01
Overview
Phase 2, single-arm trial of docetaxel and samarium-153 lexidronam in prostate cancer (PCa), sponsored by Gustave Roussy. Primary endpoint: Time to Progression. Started Jan 2004; status: terminated.
02
Drugs
docetaxelsamarium-153 lexidronam
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00126230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126230.